Technical Analysis for ADRO - Aduro Biotech, Inc.

Grade Last Price % Change Price Change
grade C 3.67 -5.17% -0.20
ADRO closed down 5.17 percent on Friday, March 22, 2019, on 53 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ADRO trend table...

Date Alert Name Type % Chg
Mar 22 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Mar 22 Bollinger Band Squeeze Range Contraction 0.00%
Mar 22 Stochastic Reached Oversold Weakness 0.00%
Mar 22 BB Squeeze + Lower Band Touch Range Contraction 0.00%
Mar 22 Below Lower BB Weakness 0.00%
Mar 22 Lower Bollinger Band Touch Weakness 0.00%
Mar 22 Oversold Stochastic Weakness 0.00%
Mar 21 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -5.17%
Mar 21 Bollinger Band Squeeze Range Contraction -5.17%
Mar 20 Non-ADX 1,2,3,4 Bullish Bullish Swing Setup -6.14%

Older signals for ADRO ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Aduro BioTech, Inc., a clinical-stage immuno-oncology company, focuses on the development of technology platforms designed to stimulate robust and durable immune responses against cancer. Its lead product candidate is CRS-207, which is in a Phase IIb clinical trial for the treatment of metastatic pancreatic cancer and unresectable malignant pleural mesothelioma. The company's cyclic dinucleotides product candidates are synthetic small molecule immune modulators that target and activate Stimulator of Interferon Genes receptor. Aduro BioTech, Inc. has collaboration agreement with Janssen Biotech, Inc. to develop drugs for the treatment of prostate and lung cancers. The company was formerly known as Oncologic, Inc. and changed its name to Aduro BioTech, Inc. in June 2008. Aduro BioTech, Inc. was founded in 2000 and is based in Berkeley, California.
Medicine Cancer Cancer Immunotherapy Technology Platforms Metastatic Pancreatic Cancer Johnson & Johnson Lung Cancers
Is ADRO a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 1 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 9.85
52 Week Low 2.34
Average Volume 595,897
200-Day Moving Average 4.9163
50-Day Moving Average 3.5206
20-Day Moving Average 4.0195
10-Day Moving Average 3.947
Average True Range 0.2591
ADX 25.0
+DI 19.5492
-DI 18.385
Chandelier Exit (Long, 3 ATRs ) 3.7227
Chandelier Exit (Short, 3 ATRs ) 4.4473
Upper Bollinger Band 4.3661
Lower Bollinger Band 3.6729
Percent B (%b) 0.0
BandWidth 17.245926
MACD Line 0.0623
MACD Signal Line 0.1294
MACD Histogram -0.0671
Fundamentals Value
Market Cap 273.83 Million
Num Shares 74.6 Million
EPS -1.56
Price-to-Earnings (P/E) Ratio -2.35
Price-to-Sales 35.46
Price-to-Book 2.36
PEG Ratio 0.05
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.06
Resistance 3 (R3) 4.10 4.02 4.00
Resistance 2 (R2) 4.02 3.92 4.00 3.97
Resistance 1 (R1) 3.84 3.86 3.80 3.80 3.95
Pivot Point 3.76 3.76 3.74 3.74 3.76
Support 1 (S1) 3.58 3.66 3.54 3.54 3.39
Support 2 (S2) 3.50 3.60 3.48 3.37
Support 3 (S3) 3.32 3.50 3.35
Support 4 (S4) 3.28